1644



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PHTZ

Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and

Scott Siegel

10/043,432

Group Art Unit:

1644

RECEIVED

Filed:

January 10, 2002

Examiner:

Not Assigned

OCT 1 8 2002

Confirmation No.:

Application No.:

3288

TECH CENTER 1600/2900

Title:

METHODS OF TREATING CACHEXIA WITH CHIMERIC ANTI-TNF

ANTIBODIES

| CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the Unite States Postal Service with sufficient postage as First Class Mail in an envelo | | | | | | | | |
|--|--|--|--|--|--|--|--|--|
| addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, V | | | | | | | | |
| Date Signature | | | | | | | | |
| Linda M. Amato | | | | | | | | |
| Typed or printed name of person signing certificate | | | | | | | | |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents P.O. Box 2327

| 1 .0. 1 | 30X 2321 |
|---------|--|
| Arling | gton, VA 22202 |
| Sir: | |
| This I | nformation Disclosure Statement is submitted: |
| [] | under 37 CFR 1.129(a), or (First/Second submission after Final Rejection) |
| [X] | under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including CPA, or a Request for Continued Examination). |
| [] | under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or |
| | [] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) |
| [] | under 37 CFR 1.97(d) together with: |

a Statement under 37 CFR 1.97(e), as checked below, and
 a \$180.00 fee under 37 CFR 1.17(p), or
 (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
 under 37 CFR 1.97(i):

 Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
 (Filed after payment of issue fee)

Examiner

| | | | • | | | |
|-----------------------|---|-----------------------|--|--|--|--|
| Staten | nent Un | ider 37 | <u>CFR 1.97(e)</u> | | | |
| [] | any co | ommuni | om a foreign patent office in a counterpart foreign application, and, to the undersigned, after making reasonable inquiry, no item of information contained disclosure statement was known to any individual designated in 37 CFR three months prior to the filing of this Information Disclosure Statement. 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 mation contained in the Information Disclosure Statement was cited in a om a foreign patent office in a counterpart application and this communication | | | |
| [] | No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. | | | | | |
| Staten | ent Un | der 37 (| CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 | | | |
| [] | comm was no | unication of receiver | information contained in the Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart application and this communication ved by any individual designated in § 1.56(c) more than thirty days prior to the information Disclosure Statement. | | | |
| [X] | Enclosed herewith is form PTO-1449: | | | | | |
| | [] Copies of the cited references are enclosed. | | | | | |
| | [X] | Applio | s of cited references are enclosed except those entered in prior application, U.S. cation No. <u>09/927,703</u> , to which priority under 35 U.S.C. 120 is claimed. The applications contains copies of the cited references. | | | |
| | [] | • | | | | |
| | [X] | | concise explanation" requirement (non-English references) for references AN7 and under 37 CFR 1.98(a)(3) is satisfied by: | | | |
| | | [] | the explanation provided on the attached sheet. | | | |
| | | [] | the explanation provided in the Specification. | | | |
| | | [] | submission of the enclosed International Search Report. | | | |
| | | [X] | the enclosed English language abstracts and also reference AH2, which is a U.S. equivalent of AN7. Copies of references AH2, AN7 and AO7 are enclosed in prior application, U.S. Application No. <u>09/927,703</u> , to which priority under 35 U.S.C. 120 is claimed. | | | |
| [X] | Applic | ant requ | uests that the following pending applications be considered: | | | |
| xaminer's Initials | | | | | | |
| | | John C | atent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona, Ghrayeb, David M. Knight and Scott Siegel, filed August 23, 2002, Docket No.: 005-025 | | | |
| | | | | | | |

Date

[X] The specification for the above cited co-pending application is identical to the present specification (10/043,432). Therefore, only a copy of the current claims for this application is enclosed. Copies of the specifications of the co-pending application will be provided upon request.
 [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.
 The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

| [] | A check for the fee noted above is enclosed, or the fee has been included in the check with the |
|-----|---|
| | accompanying Reply. A copy of this Statement is enclosed. |

- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Deirdre E. Sanders

Registration No.: 42,122 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated:

October 9, 2002

| | 9 REPRO | DUCED | · | ATTORNEY DOCKET NO. 0975.1005-017 | | TION NO. 3,432 | | | | |
|--|----------|--|---------------|---|---------------|----------------|------------------------|-----------|--|--|
| PE, | INFOR | MATION DISCLOSURE CI IN AN APPLICATION | ITATION | APPLICANT Junming Le et al. | <u> </u> | | | · | | |
| October 9, 2002 (We several sheets if necessary) | | | | FILING DATE January 10, 2002 | GROUP 1644 | | | | | |
| · . | SE SE | | U.S. | PATENT DOCUMENTS | L | | | | | |
| EXAM- INER INI- TIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB~ CLASS | FILING II APPROP | F | | |
| | AE2 | 4,816,567 | 03/28/89 | Cabilly et al. | † | | | | | |
| | AF2 | 5,075,236 | 12/24/91 | Yone et al. | | REC | FIVE | <u>:D</u> | | |
| - | AG2 | 5,959,087 | 09/28/99 | Rathjen et al. | | | 8 200 | | | |
| | AH2 | 5,360,716 | 11/01/94 | Ohmoto, Y. et al. | T | ECH CENT | | | | |
| | | | 700774 | N. D. H. D. C. D. | | | | | | |
| | | | FOREIG | N PATENT DOCUMENTS | | SUB- | TRANSL | ATTON | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | CLASS | YES | NO | | |
| | AM7 | WO92/01059 | 23 JAN 92 | PCT | | | | | | |
| | AN7 | 02-227095 | 10 SEP 90 | JP | | | Х | | | |
| | A07 | 61-047500 | 07 MAR 86 | JP | | | Х | | | |
| | | | | | | | | | | |
| | <u> </u> | | | | | | | | | |
| | | OTHER DOCUMENTS | (Including Au | thor, Title, Date, Pertinen | t Pages, | Etc.) | | | | |
| · | AT11 | Yan, L. et al., "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha", Chinese J. Biotechnology, 7(2):121-126 (1991). | | | | | | | | |
| ٨ | AU11 | Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", Hybridoma, 19(6):463-471 (2000). | | | | | | | | |
| | AV11 | Paul, W.E. (Ed.), Fundamental Immunology, 3 rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993). | | | | | | | | |
| | AW11 | Borrebaeck, C.A.K. (Ed.), Antibody Engineering, 2 nd Edition, Pub. Oxford University Press, p. 291 (1995). | | | | | | | | |
| | AX11 | Socher, S. et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor", Proc. Natl. Acad. Sci., USA 84:8829-8833 (1987). | | | | | | | | |
| | AY11 | Goh, C., "Tumour Necrosis Factors in Clinical Practice", Annals of the Academy of Medicine, 19(2):235-239 (1990). | | | | | | | | |
| | | | | | | | | | | |
| EXAMIN | NER | <u> </u> | | DATE CONSIDERED | | | <u> </u> | | | |
| | | | | | | | | | | |